- Home
- ACN vs AMGN Comparison
ACN vs AMGN Comparison
Compare ACN & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACN
- AMGN
- Stock Information
- Founded
- ACN 1989
- AMGN 1980
- Country
- ACN Ireland
- AMGN United States
- Employees
- ACN N/A
- AMGN N/A
- Industry
- ACN Business Services
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACN Consumer Discretionary
- AMGN Health Care
- Exchange
- ACN Nasdaq
- AMGN Nasdaq
- Market Cap
- ACN 174.8B
- AMGN 156.2B
- IPO Year
- ACN N/A
- AMGN N/A
- Fundamental
- Price
- ACN $307.97
- AMGN $265.86
- Analyst Decision
- ACN Buy
- AMGN Buy
- Analyst Count
- ACN 19
- AMGN 19
- Target Price
- ACN $377.89
- AMGN $324.37
- AVG Volume (30 Days)
- ACN 2.9M
- AMGN 2.8M
- Earning Date
- ACN 06-20-2025
- AMGN 05-01-2025
- Dividend Yield
- ACN 1.92%
- AMGN 3.58%
- EPS Growth
- ACN 9.77
- AMGN 56.16
- EPS
- ACN 12.12
- AMGN 10.94
- Revenue
- ACN $67,221,493,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- ACN $6.82
- AMGN $7.19
- Revenue Next Year
- ACN $5.67
- AMGN $2.37
- P/E Ratio
- ACN $25.41
- AMGN $24.30
- Revenue Growth
- ACN 4.10
- AMGN 15.56
- 52 Week Low
- ACN $275.01
- AMGN $253.30
- 52 Week High
- ACN $398.35
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- ACN 56.42
- AMGN 34.80
- Support Level
- ACN $303.20
- AMGN $268.81
- Resistance Level
- ACN $313.25
- AMGN $291.61
- Average True Range (ATR)
- ACN 5.53
- AMGN 7.54
- MACD
- ACN 3.28
- AMGN -0.76
- Stochastic Oscillator
- ACN 84.03
- AMGN 0.76
About ACN Accenture plc (Ireland)
Accenture is a leading global IT services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.